Spyre Therapeutics, INC Form 4 insider transactions

Spyre Therapeutics' CEO, Cameron Turtle, was granted 528,000 stock options with an exercise price of $30.61, vesting over four years.

Spyre Therapeutics' Chief Medical Officer, Sheldon Sloan, was granted 140,000 stock options with an exercise price of $30.61.

Spyre Therapeutics, Inc. granted 140,000 stock options to Chief Legal Officer Heidy King-Jones with an exercise price of $30.61, vesting over four years.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on January 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $435,463.50 under a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 45,000 shares of common stock for approximately $1.05 million under a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics CFO Scott L. Burrows sold 18,428 shares of common stock to cover tax liabilities related to RSU settlement.

Key directors Peter Harwin and Tomas Kiselak, associated with Fairmount Funds, were granted stock options to purchase 50,000 shares of Spyre Therapeutics common stock, vesting over 12 months.

Spyre Therapeutics, Inc. director Laurie Stelzer was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Spyre Therapeutics, Inc. Director Sandra Milligan was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Spyre Therapeutics, Inc. Director Mark C. McKenna was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Michael Thomas Henderson, a Director at Spyre Therapeutics, Inc., was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 equal monthly installments.

Spyre Therapeutics, Inc. Director Jeffrey W. Albers was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, was granted stock options for 95,500 shares on January 15, 2025.

Spyre Therapeutics' Chief Medical Officer, Sheldon Sloan, was granted stock options for 95,500 shares on January 15, 2025.

Cameron Turtle, CEO of Spyre Therapeutics, was granted options to purchase 370,000 shares of common stock on January 15, 2025, according to a recent SEC filing.

Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics, was granted stock options for 95,500 shares.

Director Michael Henderson reports receiving 105,379 shares of Spyre Therapeutics common stock through a pro-rata distribution from a limited liability company.

Director Jeffrey W. Albers sold 6,700 shares of Spyre Therapeutics (SYRE) common stock at an average price of $36.7631, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Jeffrey W. Albers, a director of Spyre Therapeutics, Inc., sold 300 shares of common stock at a price of $36.43 per share on October 25, 2024, according to a Form 4 filing with the SEC.

Chief Medical Officer of Spyre Therapeutics, Sheldon Sloan, was granted options to purchase 400,000 shares of common stock on October 1, 2024.

Scott L. Burrows, CFO of Spyre Therapeutics, sold 18,531 shares of common stock to cover tax liabilities related to the settlement of restricted stock units.

Fairmount Funds Management LLC, along with directors Peter Harwin and Tomas Kiselak, report the acquisition of stock options in Spyre Therapeutics.

Director Sandra Milligan acquired stock options for 21,980 shares of Spyre Therapeutics common stock on May 14, 2024.

Director Jeffrey W. Albers acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. common stock on May 14, 2024.

Director Laurie Stelzer acquired stock options for 11,323 shares of Spyre Therapeutics common stock on May 14, 2024.

Director Michael Thomas Henderson acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. on May 14, 2024.

Fairmount Funds Management LLC, along with related entities and individuals, converted Series A Preferred Stock into Common Stock of Spyre Therapeutics, Inc. on April 25, 2024.